TQB3002

TQB3002 is a fourth-generation, oral small-molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It acts by competitively binding to the ATP site of the intracellular tyrosine kinase domain, thereby inhibiting EGFR phosphorylation and downstream signaling. This results in tumor cell death. TQB3002 has demonstrated potent inhibitory activity against EGFR single mutations (such as EGFRd746-750 and EGFRL858R), double mutations (EGFRd746-750/T790M and EGFRL858R/T790M), and triple mutations in preclinical studies, with dose-dependent tumor growth inhibition observed in vivo. The drug is being developed primarily for advanced cancers, including solid tumors resistant to earlier generations of EGFR inhibitors[1][3][5][7]. Developed by Chia Tai Tianqing Pharmaceutical Group.

Other names

TQB-3002TQB3002TQB 3002